IOL Chemicals and Pharmaceuticals Limited has addressed a procedural delay concerning the submission of its shareholding pattern for the third quarter of the fiscal year 2026. The company's board commented on the one-day delay in filing the document under Regulation 31.

The submission of the shareholding pattern was scheduled for May 20, 2026. The delay represents a minor deviation from the standard regulatory timeline required for such disclosures. The board's comments highlight the specific nature of the lapse in relation to the scheduled filing date.

Regulatory Context

The shareholding pattern is a critical disclosure required by market regulations, providing transparency regarding the ownership structure of the company. Regulation 31 mandates the timely submission of this data to ensure that investors and the market have access to current information about share distribution.

While the delay is brief, the company has formally acknowledged the occurrence through its board's statement. The document in question pertains specifically to the quarter ending December 31, 2025, reflecting the shareholding positions as of that date.

IOL Chemicals and Pharmaceuticals Limited disclosed on 09 May 2026 that it has received an Order-In-Original (O-I-O) from the Additional Commissioner of Customs, Kandla, imposing a cumulative levy of Rs. 2,05,94,796/-. The order was received by the company on 08 May 2026 and was disclosed to the stock exchanges under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Nature of the Order and Allegations

The Order-In-Original alleges that IOL Chemicals and Pharmaceuticals incorrectly availed exemption benefits under the ASEAN-India Free Trade Agreement (FTA) by submitting Certificates of Origin that did not conform to the prescribed format under Notification No. 46/2011-Customs read with ASEAN-India FTA Rules of Origin. The authority has confirmed a demand of differential Customs duty along with associated penalties and fines as a result of this alleged non-compliance.

Breakdown of the Levy

The total aggregate levy of Rs. 2,05,94,796/- comprises multiple components as detailed below:

Company's Response and Financial Impact

IOL Chemicals and Pharmaceuticals has stated that it will be filing an appeal against this order with the appropriate authority. The company has also clarified that the aforesaid levy does not have any material impact on its financials, nor does it have any impact on its operational or other activities.

Disclosure Details

The requisite disclosure was made in accordance with Regulation 30 of the Listing Regulations, read with Clause 20 of Para A of Part A of Schedule III of the Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023. The disclosure was signed by Abhay Raj Singh, Sr. Vice President & Company Secretary of IOL Chemicals and Pharmaceuticals Limited.